The FDA has rejected Genentech's bid to put its experimental drug for wet, age-related macular degeneration on a regulatory fast track. Genentech, however, said the rejection won't affect its planned submission of the drug for regulatory approval in December. Genentech also plans to launch another late-stage trial of Lucentis by year's end. Drug developers have been closely following Lucentis, which many believe has the potential to outperform Eyetech's recently-approved Macugen.
- read this AP story [1] for more
ALSO: The TNKase clot-busting drug from Genentech and Ingelheim Boehringer is not safe for opening arteries prior to angioplasty, according to the results of a new study. Story [2]
Links:
[1] http://www.businessweek.com/ap/financialnews/D8CFFHFG1.htm?campaign_id=apn_home_down&chan=db
[2] http://www.insidebayarea.com/businessnews/ci_3007517